• Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy
• Our team at PharmaShots has compiled a list of top 20 oncology companies based on their 2020 oncology revenue
• In in the list of top 20 companies- BMS secured the top position with total revenue of $28B from oncology segment in 2020- followed by Roche and Merck with $26B & $15B

Oncology Segment Revenue: $0.23B

Founding Year: 1984

Market Cap: $11.03B

Total Employees: 22,739

Headquarter: Hyderabad- India

Stock Exchange: NSE

Dr.Reddy is an Indian Pharmaceutical company that is mainly involved in developing a wide range of generic formulations and proprietary products. The company focuses on multiple therapeutic areas including oncology- cardiovascular- dermatology- gastrointestinal- diabetology- pain management- and nephrology. In September 2020- Dr. Reddy's Laboratories launched Faslodex (fulvestrant) injection which is used to treat metastatic breast cancer. The company generated a sale of $0.23B from its oncology segment in 2020.

Oncology Segment Revenue: $0.30B

Founding Year: 2010

Market Cap: $32.58B

Total Employees: 5,100

Headquarter:  Beijing- China

Stock Exchange: HKG

BeiGene is a global biotechnology company that focuses mainly on developing medicines for cancer treatment. In June 2020- BeiGene reported EMA's acceptance of its marketing authorization application for Brukinsa (zanubrutinib) for the treatment of patients with Waldenstrom's Macroglobulinemia. In 2020- BeiGene's key drug- Brukinsa generated total sales of $0.04B and the company generated total revenue of $0.30B from the oncology segment.

Oncology Segment Revenue: $0.39B

Founding Year: 2005

Market Cap: $49.86B

Total Employees: 16,033

Headquarter: Tokyo- Japan

Stock Exchange: TYO

Daiichi Sankyo is a global pharmaceutical company that focuses on developing novel therapies in therapeutic areas including oncology and rare diseases. In May 2020- Daiichi Sankyo launched Enhertu in Japan for patients with metastatic breast cancer. In 2020- the company's key drug- Trastuzumab deruxtecan (Enhertu) generated total sales of $0.39B.

Oncology Segment Revenue: $0.51B

Founding Year: 2000

Market Cap: $100.88B

Total employees: 94,066

Headquarter: Brentford- United Kingdom

Stock Exchange: LON

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company that focuses on developing therapies in areas including oncology- respiratory- and immuno-inflammation. In August 2020- FDA approved GSK's Blenrep for the treatment of patients with relapsed or refractory multiple myeloma. With its two approved drugs- Zezula and Blenrep- GSK generated total revenue of $0.51B from its oncology segment in 2020.

Oncology Segment Revenue: $0.67B

Founding Year: 1987

Market Cap: $89.26B

Total Employees: 13,600

Headquarter: California- United States

Stock Exchange: NASDAQ

Gilead Sciences is an American biopharmaceutical company that focuses on researching and developing medicines in areas including HIV/AIDS- oncology- liver diseases- and hematology- inflammatory and respiratory. In October 2020- Gilead Sciences acquired Immunomedics. Gilead's oncology drug- Yescarta recorded total sales of $0.56B in 2020. The company generated total revenue of $0.67B from its oncology segment in 2020.

Oncology Segment Revenue: $0.97B

Founding Year: 1973

Market Cap: $126.55B

Total Employees: 99,412

Headquarter: Paris- France

Stock Exchange: EPA

Sanofi is a French multinational pharmaceutical company that focuses on developing novel therapies for oncology- cardiovascular- neurology- immunology- and inflammation. In June 2020- European Commission approved Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma. Sanofi's leading oncology drug- Jevtana recorded sales of $0.65B last year. In 2020- Sanofi generated total revenue of $0.97B from its oncology segment.

Oncology Segment Revenue: $1.68B

Founding Year: 1863

Market cap: $55.01B

Total Employees: 99,538

Headquarter: Leverkusen- Germany

Stock Exchange: ETR

Bayer is a German multinational pharmaceutical company with a focus on cancer- cardiovascular- and kidney diseases. In March 2020- Nubeqa received EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer. Bayer's leading drug- Nexavar recorded total sales of $0.78B last year. In 2020- Bayer generated total revenue of $1.68B from its oncology segment.

Oncology Segment Revenue: $2.06B

Founding Year: 1991

Market Cap: $16.50B

Total Employees: 1,773

Headquarter: Delaware- United States

Stock Exchange: NASDAQ

Incyte is an American multinational pharmaceutical company that focuses on multiple therapeutic areas including oncology- inflammation and autoimmunity. In May 2020- the US FDA approved Tabrecta (capmatinib) for the treatment of patients with metastatic NSCLC with METex14. The leading oncology drug of the company- Jakafi recorded total sales of $1.93B while the total revenue of the company is $2.06B from its oncology segment.

Oncology Segment Revenue: $3.76B

Founding Year: 1781

Market Cap: $54.41B

Total Employees: 47,099

Headquarter: Tokyo- Japan

Stock Exchange: TYO

Takeda is a Japanese multinational pharmaceutical company that develops innovative therapies in areas including oncology- rare diseases- and gastroenterology. In May 2020- the US FDA approved Takeda Alunbrig as a 1L treatment for patients diagnosed with a rare and serious form of lung cancer. Last year- the company generated total revenue of $3.76B from its oncology segment.

Oncology Segment Revenue: $4.47B

Founded Year: 2005

Market cap: $32.57B

Total Employees: 15,455

Headquarter: Tokyo- Japan

Stock Exchange: TYO

Astellas Pharma is a Japanese multinational pharmaceutical company that focuses on developing novel therapies for therapeutic areas including oncology- nephrology- urology- and transplantation. In 2020- Astellas acquired Audentes Therapeutics- and its product- Xtandi received Xtandi's approval in NMPA for the treatment of non-mCRPC. Xtandi (lead drug) contributes 90% of the total oncology segment i.e $4.14B whereas Astellas generated total revenue of $4.47B from the oncology segment.

Oncology Segment Revenue: $5.31B

Founding Year: 1876

Market Cap: $243.78B

Total Employees: 34,960

Headquarter: Indiana- United States

Stock Exchange: NYSE

Eli Lilly is an American pharmaceutical company that deals in oncology- endocrinology- neurodegenerative diseases- immunology- pain- and migraine. In 2020- Selpercatinib (Retevmo) was granted accelerated approval by the FDA for thyroid and lung cancer. Alimta- the leading candidate of the company recorded total sales of $2.33B whereas the total revenue oncology segment is $5.31B in 2020

Oncology Segment Revenue: $6.65B

Founding Year: 2013

Market Cap: $195.03B

Total Employees: 47,000

Headquarter: Illinois- United States

Stock Exchange: NYSE

Abbvie is an American pharmaceutical company that focuses on developing novel products for therapeutic areas including oncology- immunology- dermatology- and virology. In 2020- Venclexta received FDA approval for AML and Imbruvica recorded total sales of $5.31B. Last year- Abbvie generated total revenue of $6.65B from its oncology segment.

Oncology Segment Revenue: $8.32B

Founding Year: 1980

Market Cap: $125.42B

Total Employees: 24,300

Headquarter: California- United States

Stock Exchange: NASDAQ

Amgen is an American biopharmaceutical company that is working on multiple therapeutic areas including oncology- neurology- immunology- nephrology- and inflammation. In December 2020- FDA approved Riabni- a biosimilar to Rituxan- for the treatment of adult patients with NHL & CLL. Amgen's key drug- Xgeva recorded total sales of $1.89B while the company generated total revenue of $8.32B from its oncology segment.

Oncology Segment Revenue: $10.85B

Founding Year: 1999

Market Cap: $181.52B

Total Employees: 76,100

Headquarter: Cambridge- United Kingdom

Stock Exchange: NASDAQ

AstraZeneca is a multinational pharmaceutical and biotechnology company that focuses on a portfolio of products in areas including oncology- cardiovascular- gastrointestinal- infection- respiratory- and inflammation. In September 2020- AZ'sImfinzi was approved in the EU for 1L treatment of adults with ES-SCLC. Last year- Tagrisso recorded total sales of $4.32B while the company's total revenue is $10.85B from its oncology segment.

Oncology Segment Revenue: $10.86B

Founding Year: 1849

Market Cap: $262.11B

Total Employees: 78,500

Headquarter: New York- United States

Stock Exchange: NYSE

Pfizer is an American multinational pharmaceutical and biotechnology company that develops novel medicines and vaccines for therapeutic areas including oncology- immunology- cardiology- endocrinology and neurology. In June 2020- the EU approved Bavencio as a treatment for patients with LA or metastatic urothelial carcinoma. Pfizer's leading drug- Ibrance recorded 50% of the total sales of the company in the oncology segment i.e. $5.39B.

Oncology Segment Revenue: $12.36B

Founding Year: 1887

Market Cap: $452.52B

Total Employees: 134,500

Headquarter: New Jersey- United States

Stock Exchange: NYSE

Johnson and Johnson is an American multinational pharmaceutical company that has a product portfolio of multiple therapeutic areas including CV- oncology- immunology- and endocrinology. In its oncology segment- J&J focuses on core diseases including prostate cancer and multiple myeloma. The company's leading drug- Darzalex recorded total sales of $4.19B whereas the total revenue is $12.36B in the oncology segment.

Oncology Segment Revenue: $14.71B

Founding Year: 1996

Market Cap: $222.98B

Total Employees: 105,794

Headquarter: Basel- Switzerland

Stock Exchange: SWX

Novartis is a Swiss multinational pharmaceutical company that works in multiple disease areas including oncology- hepatology- immunology- dermatology- musculoskeletal diseases- neuroscience- and ophthalmology. In 2020- Novartis generated total revenue of $14.71B from its oncology segment.

Oncology Segment Revenue: $15.83B

Founding Year: 1891

Market Cap: $190.76B

Total Employees: 74,000

Headquarter: New Jersey- United States

Stock Exchange: NYSE

Merck is an American multinational pharmaceutical company focused on developing innovative medicines in areas including oncology- infectious diseases- respiratory and immunology. In 2020- FDA approved Merck Keytruda in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer. Keytruda recorded total sales of $14.38B whereas the total revenue of the company is $15.83B in its oncology segment.

Oncology Segment Revenue: $26.37B

Founding Year: 1896

Market Cap: $380.16B

Total Employees: 101,465

Headquarter: Basel- Switzerland

Stock Exchange: SWX

Roche is a Swiss multinational pharmaceutical company focused on developing products in areas including oncology- immunology- and ophthalmology- cardiovascular and respiratory. In December 2020- EC approved Roche Phesgo for people with HER2- breast cancer. Roche's Avastin recorded total sales of $5.64B whereas the company generated total revenue of $26.37B from its oncology segment.

Oncology Segment Revenue: $28.14B

Founding Year: 1887

Market Cap: $144.86B

Total Employees: 30,250

Headquarter: New York- United States

Stock Exchange: NYSE

BMS is a global biopharmaceutical company focused on developing innovative products in oncology- immunology- and hematology- cardiovascular. In November 2020- BMS received EC's approval for Opdivo + Yervoy with two cycles of CT for 1L treatment of mNSCLC. BMS Revlimid recorded total sales of $12.10B while the company generated total revenue of $28.14B from its oncology segment.

Source: Company annual reports- SEC filings- press releases- and company websites

Market Cap source: Google finance (as of 09th September 2021)

All revenues are reported in USD.

Related Post: Top 20 Oncology Companies by Total Products of 2019